About Lutris Pharma
Lutris Pharma is a Healthcare company based in Tel Aviv (Israel) founded in 2016 by Antoni Ribas. Provider of anti-cancer therapy. Lutris Pharma has raised $30 million across 1 funding round from investors including Columbus Venture Partners, Pontifax Venture Capital and Peregrine. Its chief executive, as recorded, is Noa Shelach. Lutris Pharma offers products and services including LUT014 and LUT-RD. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.
Company details
Lutris Pharma was founded in 2016 in Tel Aviv, Israel, within the pharmaceutical sector. Focus is placed on developing EGFR inhibitors for anti-cancer treatment, aimed at minimizing dose-limiting dermal toxicity. The proprietary small molecule LUT014, a B-Raf-based inhibitor, is being advanced to reduce acneiform lesions and is currently in phase 1 clinical trials. Operations center on oncology drug innovation.
- Headquarters Tel Aviv, Israel
- Founders Antoni Ribas
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website lutris-pharma.com
- Social LinkedIn
- Total Equity Funding$30M (USD)
in 1 rounds
- Latest Funding Round$30M (USD), Series B
Jan 2025
- InvestorsColumbus Venture Partners
& 3 more
Products & Services of Lutris Pharma
Lutris Pharma offers a comprehensive portfolio of products and services, including LUT014 and LUT-RD.
Topical gel that reduces acneiform lesions from EGFR Inhibitors.
Gel treatment for radiation dermatitis in cancer patients.
Funding Insights of Lutris Pharma
Lutris Pharma has successfully raised a total of $30M through 1 strategic funding round. The most recent funding activity was a Series B round of $30 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30M
- Total Rounds 1
- Last Round Series B — $30M
- First Round $30M
(Jan 2025)
- Investors Count 4
All 1 funding rounds of Lutris Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $30M | Series B | – | Columbus Venture Partners, Pontifax |
4 investors in total: 4 institutional.
Investors in Lutris Pharma
Lutris Pharma has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Columbus Venture Partners, Pontifax Venture Capital and Peregrine.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Columbus Venture Partners is focused on biotechnology investment funds. | columbusvp.com | Valencia, Spain | ||
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
Peregrine is focused on healthcare innovation through strategic global investments. | peregrinevc.com | Or Yehuda, Israel | ||
Venture capital investments in healthcare are focused on by aMoon. | amoon.fund |
Investor details for Lutris Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lutris Pharma
3 people are tracked at Lutris Pharma (3 in leadership).
| Name | Role | Group |
|---|---|---|
Antoni Ribas | Founder & Chairman | Leadership |
Noa Shelach | CEO | Leadership |
Mori Arkin | Board of Directors | Leadership |
Complete people profiles for Lutris Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Lutris Pharma
2 dated milestones of Lutris Pharma across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Lutris Pharma is founded.
- Funding First funding round of $30.0M.
Web traffic of Lutris Pharma
The website of Lutris Pharma (lutris-pharma.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 92.1% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lutris Pharma
Complete news archive for Lutris Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lutris Pharma
Lutris Pharma was founded in 2016 and raised its 1st funding round 9 years after it was founded.
Lutris Pharma is headquartered in Tel Aviv, Israel.
Noa Shelach is the CEO of Lutris Pharma, as recorded in our data.
Lutris Pharma is a funded company, having raised a total of $30M across 1 funding round to date. The company's 1st funding round was a Series B of $30M, raised on Jan 2025.
Lutris Pharma was founded in 2016 in Tel Aviv, Israel, within the pharmaceutical sector. Focus is placed on developing EGFR inhibitors for anti-cancer treatment, aimed at minimizing dose-limiting dermal toxicity. The proprietary small molecule LUT014, a B-Raf-based inhibitor, is being advanced to reduce acneiform lesions and is currently in phase 1 clinical trials. Operations center on oncology drug innovation.
Lutris Pharma offers LUT014 and LUT-RD.
Lutris Pharma has 4 investors. Key investors include Columbus Venture Partners, Pontifax Venture Capital, Peregrine, and aMoon.